Publications by authors named "Arthur Michon-Colin"
X-linked hypophosphatemic rickets (XLH) is a genetic cause of renal hypophosphatemia due to inactivation of the PHEX gene, with an inappropriate concentration of fibroblast growth factor 23 (FGF23). Burosumab, an anti-FGF23 monoclonal antibody, is a validated treatment for XLH, but its use in patients with chronic kidney disease (CKD) has not been validated. A 61-year-old man with XLH developed CKD during follow-up.
View Article and Find Full Text PDFNephrolithiasis affects around 10% of the population and is frequently associated with impaired dietary factors. The first one is insufficient fluid intake inducing reduced urine volume, urine supersaturation, and subsequently urinary lithiasis. Kidneys regulate 24 h urine volume, which, under physiological conditions, approximately reflects daily fluid intake.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at how two substances, copeptin and iFGF23, in patients with chronic kidney disease (CKD) might predict bad health outcomes.
- It involved 329 CKD patients and found that higher levels of iFGF23 were linked to worse kidney health and more deaths, while copeptin did not show this link.
- The researchers suggest that checking iFGF23 levels could help doctors better monitor CKD patients, but copeptin levels may not be as helpful.
Background: In late 2018, the production of Chromium-labelled ethylenediamine tetra-acetic acid (Cr-EDTA), a validated and widely used radio-isotopic tracer for measuring glomerular filtration rate, was halted. Technetium-99m-diethylenetriaminepentaacetic acid (Tc-DTPA) has been validated for GFR measurement with a single bolus injection, a procedure not suitable in patients with extracellular compartment hyperhydration. In such cases, a bolus followed by continuous infusion of the tracer is required.
View Article and Find Full Text PDF